ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
THE CONTROL OF APOPTOSIS AND DRUG-RESISTANCE IN OVARIAN-CANCER - INFLUENCE OF P53 AND BCL-2
Author(s): ELIOPOULOS AG, KERR DJ, HEROD J, HODGKINS L, KRAJEWSKI S, REED JC, YOUNG LS
Source: ONCOGENE    Volume: 11    Issue: 7    Pages: 1217-1228    Published: OCT 5 1995  
Times Cited: 217     References: 74     
Abstract: Modulation of apoptosis may influence resistance to chemotherapy and therefore affect the outcome of cancer treatment. Ovarian cancer, one of the most fatal malignancies in women, is often associated with drug resistance but the cellular pathways contributing to this effect remain obscure. We have found that Bcl-2 and p53, two proteins implicated in the control of apoptosis, are frequently expressed in fresh biopsies of primary ovarian carcinoma. Examination of Bcl-2 and p53 protein levels in pairs of cis-platin sensitive and resistant ovarian cell lines demonstrated that the resistant variants over-express Bcl-2 and/or p53, apparently due to progressive expansion of Bcl-2 and/or p53 positive subpopulations during the in vitro development of resistance. Exogenous expression of Bcl-2 or a temperature sensitive mutant p53 (ts p53) in the ovarian cell line A2780 resulted in protection from drug-induced apoptosis and a delay in drug-mediated S-phase arrest. Interestingly, p53 accumulation in response to DNA damage induced by different agents was significantly delayed and reduced in the Bcl-2 transfectants compared to the control A2780 line, suggesting that Bcl-2 may act upstream of the p53 pathway. Similarly, the induction of Bax mRNA and protein was also found to be delayed in the presence of Bcl-2. Overall, our data provide further evidence for cross-talk between Bcl-2, p53 and Bax and suggest that these genes are important determinants of drug-induced apoptosis thereby modulating resistance to chemotherapy.
Document Type: Article
Language: English
Addresses:
1. UNIV BIRMINGHAM, SCH MED, CRC, INST CANC STUDIES, BIRMINGHAM B15 2TH, W MIDLANDS ENGLAND
2. LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA
Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS
Subject Category: Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity
IDS Number: RY967
ISSN: 0950-9232
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo